Safety and Efficacy Study of IMSA101 in Refractory Malignancies

NCT04020185 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: IMSA101
DRUG: Immune checkpoint inhibitor (ICI)
DRUG: Immuno-oncology (IO) therapy

Sponsor

ImmuneSensor Therapeutics Inc.